

IN THE CLAIMS

Please cancel claims 10, 15, 16, 18, 24, 53, 55-57 and 69-70, without prejudice to Applicants' right to pursue the subject matter of these claims in another application. Please amend claims 1, 7, 12, 17, 19-21, 33, 35-37, 41, 46, 48-51, 58-59, 66 and 71 as follows:

- [Handwritten signature]*
1. (Amended) A pharmaceutical composition comprising:  
agent i) selected from the group consisting of an insulin, an insulin analog, a physiologically active fragment of said insulin and a physiologically active fragment of said insulin analog,  
agent ii) selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment and a physiologically active insulin-related peptide analog fragment, and  
agent iii) an insulin sensitizer.
2. The composition of claim 1 wherein said agent i) is an insulin.
3. The composition of claim 2 wherein said insulin is selected from the group consisting of human insulin, porcine insulin and bovine insulin.
4. The composition of claim 1 wherein said agent i) is an insulin analog.
5. The composition of claim 4 wherein said insulin analog is selected from the group consisting of Lys<sup>B28</sup> insulin, Pro<sup>K29</sup> insulin and Asp<sup>B28</sup> insulin.
6. The composition of claim 1 wherein said agent ii) is an insulin-related peptide.
- H2*
7. (Amended) The composition of claim 6 wherein said peptide is selected from the group consisting of C-peptide, glucagon-like peptide-1 (GLP-1), amylin, insulin-like growth factor-1 (IGF-1) and IGF-1 bound to binding protein 3.
8. The composition of claim 1 wherein said agent iii) is an insulin sensitizer of the glirazone family.

9. The composition of claim 1 which is stabilized for administration by a medication infusion pump.

10. (Cancelled)

11. The composition of claim 1 comprising about 1.5 to about 40 mg/ml of agent i) and about 1.5 to about 40 mg/ml of agent ii).

A3  
B  
12. (Amended) The composition of claim 1 further comprising a pharmaceutically acceptable non-ionic surfactant.

13. The composition of claim 12 wherein said non-ionic surfactant is a block copolymer of propylene oxide and ethylene oxide.

14. The composition of claim 13 comprising about 1.5 to about 40 mg/ml of agent i), about 1.5 to about 40 mg/ml of agent ii) and an amount of said non-ionic surfactant affording a concentration less than the critical micellar concentration of said composition.

15. (Cancelled)

16. (Cancelled)

A (cancel)  
17. (Amended) The composition of claim 1 comprising about 0.5 to about 40 mg/ml of agent i) and about 0.05 to about 12 mg/ml of agent iii).

18. (Cancelled)

A (cancel)  
19. (Amended) The composition of claim 1 comprising about 0.05 to about 12.5 mg/ml of agent ii) and about 0.05 to about 12.5 mg/ml of agent iii).

20. (Amended) The composition of claim 1 comprising two or more compounds of agent i), two or more compounds of agent ii), or two or more compounds of agent iii).

21. (Amended) A pharmaceutical composition comprising

i) at least one agent selected from the group consisting of an insulin, an insulin analog, a physiologically active insulin fragment and a physiologically active insulin analog fragment and

ii) at least one agent selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment and a physiologically active insulin-related peptide analog fragment, and

iii) an insulin sensitizer;

wherein said agent ii) comprises a hydrophobic portion that is coated with a pharmaceutically acceptable non-ionic surfactant.

22. The pharmaceutical composition of claim 21 wherein said non-ionic surfactant is a block copolymer of propylene oxide and ethylene oxide.

23. The pharmaceutical composition of claim 21 further comprising a pharmaceutically acceptable carrier.

24. (Cancelled)

25. The composition of claim 21 which is stabilized for administration by a medication infusion pump.

26. A method of treating diabetes comprising the step of administering to a patient in need of such treatment the pharmaceutical composition of claim 1.

27. The method of claim 26 wherein said composition is administered to said patient by a medication infusion pump.

28. The method of claim 27 wherein said medication infusion pump is reusable.
29. The method of claim 27 wherein said medication infusion pump is non-reusable.
30. The method of claim 27 wherein said medication infusion pump is implantable.
31. The method of claim 27 wherein said medication infusion pump is externally mountable.
32. The method of claim 26 wherein said composition is administered continually.

*AL*

33. (Amended) A method of treating diabetes comprising the step of administering to a patient in need of such treatment the pharmaceutical composition of claim 1 .

34. A method of treating diabetes comprising the step of administering to a patient in need of such treatment the pharmaceutical composition of claim 12.

*A7*

35. (Amended) A method of treating diabetes comprising the step of administering to a patient in need of such treatment the pharmaceutical composition of claim 14.

36. (Amended) A method of treating diabetes comprising the step of administering to a patient in need of such treatment the pharmaceutical composition of claim 17.

37. (Amended) A method of treating diabetes comprising the step of administering to a patient in need of such treatment the pharmaceutical composition of claim 19.

38. The method of claim 37 wherein said diabetes is type 2 diabetes.

39. A method of treating diabetes comprising the step of administering to a patient in need of such treatment the pharmaceutical composition of claim 20.

40. A method of treating diabetes comprising the step of administering to a patient in need of such treatment the pharmaceutical composition of claim 21.

*JLB/AS*

41. (Amended) A method of treating diabetes comprising the step of administering to a patient in need of such treatment pharmaceutical compositions a)-c), wherein

composition a) comprises

- i) at least one agent selected from the group consisting of an insulin, an insulin analog, a physiologically active fragment of said insulin and a physiologically active fragment of said insulin analog, and
- ii) a pharmaceutically acceptable carrier,

composition b) comprises

- i) at least one agent selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment and a physiologically active insulin-related peptide analog fragment, and
- ii) a pharmaceutically acceptable carrier, and

composition c) comprises

- i) an insulin sensitizer, and
- ii) a pharmaceutically acceptable carrier.

42. The method of claim 41 wherein each of said compositions is administered to said patient using a separate delivery device.

43. The method of claim 42 wherein each said delivery device is a medication infusion pump.

44. The method of claim 41 wherein each of said compositions is administered at a different rate.

45. The method of claim 41 wherein each of said compositions is administered continually.

*a9*  
46. (Amended) The method of claim 41 wherein compositions a) and b) are administered to said patient using a single delivery device.

*a10*  
47. The method of claim 46 wherein said composition b) further comprises at least one pharmaceutically acceptable non-ionic surfactant.

48. (Amended) The method of claim 41 wherein compositions a) and c) are administered to said patient using a single delivery device.

49. (Amended) The method of claim 41 wherein compositions b) and c) are administered to said patient using a single delivery device.

50. (Amended) The method of claim 41 wherein compositions a), b) and c) are administered to said patient using a single delivery device.

*CHB*  
51. (Amended) A method of making a pharmaceutical composition useful in treating diabetes, said method comprising the step of combining agents i) - iii), wherein  
agent i) is selected from the group consisting of an insulin, an insulin analog, a physiologically active fragment of said insulin and a physiologically active fragment of said insulin analog,  
agent ii) is selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment and a physiologically active insulin-related peptide analog fragment, and  
agent iii) is an insulin sensitizer.

52. The method of claim 51 wherein said agents are combined with a pharmaceutically acceptable carrier.

53. (Cancelled)

54. The method of claim 52 wherein agents i) and ii) are combined with a pharmaceutically acceptable non-ionic surfactant.

55. (Canceled)

56. (Canceled)

57. (Canceled)

58. (Amended) A method of treating diabetes and at least one side effect thereof which comprises the step of administering to a patient in need of such treatment a pharmaceutical composition comprising

- a) at least one agent selected from the group consisting of an insulin, an insulin analog, a physiologically active insulin fragment and a physiologically active insulin analog fragment;
- b) at least one agent selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment and a physiologically active insulin-related peptide analog fragment, wherein said agent is effective in treating said side effect;
- c) a pharmaceutically acceptable non-ionic surfactant, and
- d) an insulin sensitizer.

59. (Amended) A pharmaceutical composition comprising agents i) - iii), wherein agent i) is selected from the group consisting of an insulin mimetic material, agent ii) is selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment, and a physiologically active insulin-related peptide analog fragment, and agent iii) is an insulin sensitizer.

60. The composition of claim 59 wherein said agent i) is a small molecule insulin.

61. The composition of claim 60 wherein the small molecule insulin mimetic material is L-783,281.

62. The composition of claim 59 wherein said agent ii) is an insulin-related peptide.

63. The composition of claim 62 wherein said peptide is selected from the group consisting of C-peptide, GLP-1, amylin, IGF-1 and IGF-1 bound to binding protein 3.

64. The composition of claim 59 wherein said agent iii) is an insulin sensitizer of the glitazone family.

65. The composition of claim 59 which is stabilized for administration by a medication infusion pump.

*G&C 12/10/02*  
66. (Amended) The composition of claim 59 comprising about 1.5 to about 40 mg/ml of agent i), about 1.5 to about 40 mg/ml of agent ii), and about 0.05 to about 12.5 mg/ml of agent iii).

67. The composition of claim 66 further comprising a pharmaceutically acceptable non-ionic surfactant.

68. The composition of claim 67 wherein said non-ionic surfactant is a block copolymer of propylene oxide and ethylene oxide.

69. (Cancelled)

*G&C 12/10/02*  
70. (Cancelled)

*G&C 12/10/02*  
71. (Amended) The composition of claim 59 comprising two or more compounds of agent i), two or more compounds of agent ii) or two or more compounds of agent iii).